When should patients be referred for radioactive iodine (RAI) therapy?

When to Refer Patients for Radioactive Iodine (RAI) Therapy

Refer all high-risk differentiated thyroid cancer (DTC) patients for RAI therapy after total thyroidectomy; avoid RAI in very low-risk patients; and selectively refer intermediate-risk patients based on specific pathologic features and postoperative thyroglobulin levels.

Definitive Indications for RAI Referral (High-Risk Patients)

All patients with any of the following features should be referred for RAI therapy with 100–200 mCi (3.7–7.4 GBq): 1

• Extrathyroidal extension (microscopic or gross, T3/T4 disease) 1
• Lymph node metastases with >5 involved nodes or any node >3 cm 1
• Distant metastases (M1 disease to lungs, bones, or other sites) 1
• Incomplete tumor resection with positive margins 1
• Aggressive histologic variants with vascular invasion (>4 foci) 1
• Widely invasive follicular thyroid cancer 1

These patients have estimated recurrence risks of 30–100% and demonstrate clear mortality benefit from RAI therapy. 1, 2

Do NOT Refer for RAI (Very Low-Risk Patients)

The following patients should NOT be referred for RAI therapy: 1, 3

• Unifocal papillary microcarcinoma ≤1 cm (pT1a, N0) with no extrathyroidal extension, no lymph node involvement, favorable histology, and complete resection 1, 3
• Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) 1, 4

These patients have <1% recurrence risk and derive no mortality or recurrence benefit from RAI. 1, 3 Administering RAI to this group constitutes overtreatment with unnecessary radiation exposure. 3

Selective Referral Algorithm (Intermediate and Low-Risk Patients)

Intermediate-Risk Patients: Generally Refer

Refer patients with 3–20% recurrence risk who have any of the following: 1, 3

• Aggressive histologic variants (tall-cell, columnar-cell, hobnail, diffuse sclerosing, solid/trabecular) 1, 3
• Vascular invasion (any degree) 1
• Multifocal papillary microcarcinoma with extrathyroidal extension 1
• Intrathyroidal tumor <4 cm with BRAF V600E mutation (if known) 1
• Clinical N1 disease with >5 lymph nodes involved, each <3 cm 1
• RAI-avid metastatic foci in the neck on post-treatment scan 1
• Microscopic invasion of perithyroidal soft tissues 1

Use 30–100 mCi (1.1–3.7 GBq) for this group. 3, 5

Low-Risk Patients (1–4 cm, N0): Decision Framework

For patients with tumors 1–4 cm, no lymph node metastases, no extrathyroidal extension, and complete resection, use the following algorithm: 1, 3, 6

REFER for RAI if:

• Age <30 years (10-year progression risk 36%) 1
• Postoperative stimulated thyroglobulin ≥2.5 ng/mL 6
• Tumor size >2 cm with any additional risk factor (age >45, lymph node micrometastases <5 nodes) 7
• Limited access to high-quality neck ultrasound or sensitive thyroglobulin assays 1
• Patient preference after informed discussion of uncertain benefit 1, 3

If referring, use 30 mCi (1.1 GBq) with rhTSH preparation. 3, 5

DO NOT REFER for RAI if:

• Age >60 years (10-year progression risk 6%) 1
• Postoperative basal thyroglobulin <0.2 ng/mL or stimulated <1 ng/mL 1, 6
• Negative neck ultrasound at 2–3 months post-surgery 1
• Complete surgical resection with negative margins 1
• Tumor 1–2 cm without other risk factors 7

Critical Caveat on Controversial Low-Risk Group

The American Thyroid Association, European Association of Nuclear Medicine, Society of Nuclear Medicine and Molecular Imaging, and European Thyroid Association jointly acknowledge that high-quality evidence for or against RAI in low-risk patients is insufficient. 1, 3, 8 Recent SEER data suggest potential survival benefit even in low-risk disease, but this remains observational. 2 When in doubt for low-risk patients, favor observation over RAI to avoid overtreatment. 3

Special Considerations for Lymph Node Involvement

For patients with small-volume pathologic N1a metastases (<3–5 involved nodes, no metastasis >5 mm), completion thyroidectomy and RAI are not required. 4 However, if extranodal extension is present with mass size ≥4 cm, >5 lymph nodes involved, or stimulated thyroglobulin ≥10 ng/mL, refer for RAI ≥100 mCi. 9

Dosing Recommendations Upon Referral

Remnant Ablation (No Known Residual Disease)

• 30 mCi (1.1 GBq) for low-risk patients 3, 5
• 50 mCi (1.85 GBq) for intermediate-risk patients (equally effective as 100 mCi with less radiation exposure) 3, 5

Known Persistent or Metastatic Disease

• 100–150 mCi (3.7–5.6 GBq) for locoregional or distant metastases 1, 5
• Repeat every 6–12 months while RAI uptake persists and disease responds 1
• Caution with cumulative doses >150–200 mCi due to increased secondary malignancy risk 5

Common Pitfalls to Avoid

• Do not routinely use 100 mCi for simple remnant ablation – lower doses (30–50 mCi) achieve equivalent success with reduced radiation exposure 3, 5
• Do not give RAI to pT1a N0 unifocal microcarcinomas – this adds unnecessary radiation without benefit 3
• Do not ignore postoperative thyroglobulin levels – undetectable levels (<0.2 ng/mL basal or <1 ng/mL stimulated) argue strongly against RAI in low-risk patients 1, 6
• Monitor cumulative RAI exposure – doses exceeding 150–200 mCi may increase secondary primary malignancy risk 5
• Prefer rhTSH preparation over thyroid hormone withdrawal – equivalent efficacy with superior quality of life 3